Exagen (XGN) Competitors $3.84 -0.40 (-9.43%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$3.86 +0.02 (+0.52%) As of 03/28/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XGN vs. VMD, DCGO, LFMD, AIRS, SERA, BDSX, QIPT, CORBF, EUDA, and TOIShould you be buying Exagen stock or one of its competitors? The main competitors of Exagen include Viemed Healthcare (VMD), DocGo (DCGO), LifeMD (LFMD), AirSculpt Technologies (AIRS), Sera Prognostics (SERA), Biodesix (BDSX), Quipt Home Medical (QIPT), Global Cord Blood (CORBF), EUDA Health (EUDA), and Oncology Institute (TOI). These companies are all part of the "healthcare" industry. Exagen vs. Viemed Healthcare DocGo LifeMD AirSculpt Technologies Sera Prognostics Biodesix Quipt Home Medical Global Cord Blood EUDA Health Oncology Institute Exagen (NASDAQ:XGN) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk. Does the media favor XGN or VMD? In the previous week, Viemed Healthcare had 1 more articles in the media than Exagen. MarketBeat recorded 3 mentions for Viemed Healthcare and 2 mentions for Exagen. Viemed Healthcare's average media sentiment score of 1.71 beat Exagen's score of 1.44 indicating that Viemed Healthcare is being referred to more favorably in the news media. Company Overall Sentiment Exagen Positive Viemed Healthcare Very Positive Is XGN or VMD more profitable? Viemed Healthcare has a net margin of 4.87% compared to Exagen's net margin of -30.36%. Viemed Healthcare's return on equity of 8.72% beat Exagen's return on equity.Company Net Margins Return on Equity Return on Assets Exagen-30.36% -92.58% -33.74% Viemed Healthcare 4.87%8.72%6.48% Which has more volatility and risk, XGN or VMD? Exagen has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Viemed Healthcare has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Does the MarketBeat Community believe in XGN or VMD? Exagen received 21 more outperform votes than Viemed Healthcare when rated by MarketBeat users. Likewise, 58.54% of users gave Exagen an outperform vote while only 42.86% of users gave Viemed Healthcare an outperform vote. CompanyUnderperformOutperformExagenOutperform Votes2458.54% Underperform Votes1741.46% Viemed HealthcareOutperform Votes342.86% Underperform Votes457.14% Which has better valuation & earnings, XGN or VMD? Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExagen$55.64M1.24-$23.69M-$0.83-4.63Viemed Healthcare$224.26M1.28$10.24M$0.2825.96 Do insiders and institutionals have more ownership in XGN or VMD? 75.3% of Exagen shares are owned by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are owned by institutional investors. 26.1% of Exagen shares are owned by insiders. Comparatively, 20.0% of Viemed Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate XGN or VMD? Exagen currently has a consensus target price of $7.50, suggesting a potential upside of 95.31%. Given Exagen's higher probable upside, research analysts clearly believe Exagen is more favorable than Viemed Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Viemed Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 SummaryViemed Healthcare beats Exagen on 13 of the 19 factors compared between the two stocks. Remove Ads Get Exagen News Delivered to You Automatically Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XGN vs. The Competition Export to ExcelMetricExagenMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.73M$2.83B$5.63B$7.83BDividend YieldN/A22.57%4.57%4.01%P/E Ratio-4.0913.1723.3318.67Price / Sales1.24202.00387.5690.67Price / CashN/A57.5638.1634.64Price / Book2.894.356.894.23Net Income-$23.69M-$22.21M$3.20B$247.15M7 Day Performance-1.03%51.05%-2.98%-2.17%1 Month Performance10.98%12.95%1.63%-5.68%1 Year Performance141.51%-3.70%9.44%-0.74% Exagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XGNExagen4.6678 of 5 stars$3.84-9.4%$7.50+95.3%+141.5%$68.73M$55.64M-4.09220Short Interest ↓Positive NewsVMDViemed Healthcare1.0769 of 5 stars$7.30+0.8%N/A-22.9%$288.51M$224.26M27.04630News CoveragePositive NewsDCGODocGo3.055 of 5 stars$2.77+3.7%$4.89+76.6%-34.7%$282.49M$616.56M9.892,920Short Interest ↓LFMDLifeMD1.8443 of 5 stars$6.10+8.9%$11.43+87.4%-47.0%$271.96M$212.45M-9.53230Short Interest ↑AIRSAirSculpt Technologies1.2687 of 5 stars$2.74+3.8%$5.00+82.5%-62.7%$160.50M$180.35M-19.57240Short Interest ↑High Trading VolumeSERASera Prognostics0.6612 of 5 stars$4.14+9.2%N/A-61.1%$139.82M$77,000.00-4.18120Positive NewsBDSXBiodesix2.8679 of 5 stars$0.83-1.9%$2.95+255.2%-53.1%$121.24M$71.32M-2.13220Short Interest ↑Positive NewsGap DownQIPTQuipt Home Medical2.635 of 5 stars$2.34-1.3%$6.25+167.1%-46.9%$100.83M$244.72M-13.76800CORBFGlobal Cord BloodN/A$0.80flatN/A-40.7%$97.24M$196.12M0.001,200Gap DownEUDAEUDA Health0.4365 of 5 stars$3.93-3.2%N/A+100.0%$96.79M$3.81M0.002TOIOncology Institute0.4884 of 5 stars$1.24+24.5%N/A-27.8%$93.69M$378.93M-1.59660Earnings ReportNews CoverageHigh Trading Volume Remove Ads Related Companies and Tools Related Companies VMD Alternatives DCGO Alternatives LFMD Alternatives AIRS Alternatives SERA Alternatives BDSX Alternatives QIPT Alternatives CORBF Alternatives EUDA Alternatives TOI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XGN) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
